BB Biotech AG (BBZA)

Category Sector Equity Biotechnology

Some Investment Trusts include direct costs as part of their Ongoing charge, such as the annual management charge. For those that show ongoing charges as 0% or a dash please review the investment literature for details on the charges that will apply.

If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice.

Sell

Buy

arrow-up (+%)

Discount/Premium

-15.89%

Estimated NAV

57.90

Prices updated at 24 Oct 2026, 17:21

Prices minimum 15 mins delay

Prices in CHF

Investment objective

BB Biotech invests in fast-growing biotechnology companies that are developing and marketing innovative drugs. It focuses on biotech companies whose products address areas of significant unmet medical needs and that are generating above-average sales and profit growth. BB Biotech’s investment portfolio will usually consist of 20 to 35 biotechnology companies. This will include 5 to 8 large core positions, which together will account for up to 2/3 of the portfolio.New investments in mid-cap companies will have a weighting of between 1% and a maximum of 5% to ensure that both upside potential and R&D risks are adequately addressed.Non-listed companies should not exceed 10% of the portfolio.

-%

Important notice: This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements. Please refer to the FCA website which details further information in relation to sustainability disclosure requirements for retail clients.

Important documents: Please ensure that you have read the Key Information Document/Technical Guide or Product Summary document , Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and the fund information documents. These can be found within the Charges & documents section.

Annual charges

Product charges
	1.39
	1.23
	-
Minimum investment	-

Documents

Document name chevron-l-regular chevron-r-regular	Language	Date posted
Factsheet	English	31 Aug 2026
Semi-Annual Report	English	31 Mar 2026
Annual Report	English	31 Dec 2024
Key Information Document (KID)	English	29 Nov 2024

Please note that service charges will also apply. Read more about our fees.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser.

© Copyright 2026 Morningstar. All rights reserved. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

The ESG-related information, methodologies, tools, ratings, data and opinions contained or reflected herein are not directed to or intended for use or distribution to India-based clients or users and their distribution to Indian resident individuals or entities is not permitted, and Morningstar accepts no responsibility or liability whatsoever for the actions of third parties in this respect.